Sugi Predict

Sugi Predict / Targets / DUSP1

DUSP1

Dual specificity protein phosphatase 1 · P28562 · DUSP1 on Sugi Atlas →

1,157 patent compounds predicted against DUSP1, 831 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12783895 SCHEMBL12783895 0.61 12/20
SCHEMBL14096536 SCHEMBL14096536 0.75 8/20
SCHEMBL4514921 SCHEMBL4514921 0.72 7/20
SCHEMBL14096636 SCHEMBL14096636 0.75 6/20
SCHEMBL4518500 SCHEMBL4518500 0.69 6/20
SCHEMBL4501249 SCHEMBL4501249 0.66 6/20
SCHEMBL4523637 SCHEMBL4523637 0.66 6/20
SCHEMBL4513229 SCHEMBL4513229 0.65 6/20
SCHEMBL6086053 SCHEMBL6086053 0.63 6/20
SCHEMBL2862540 SCHEMBL2862540 0.58 6/20
SCHEMBL1904082 SCHEMBL1904082 1.00 5/20
SCHEMBL1904083 SCHEMBL1904083 1.00 5/20
SCHEMBL1904087 SCHEMBL1904087 1.00 5/20
SCHEMBL1904704 SCHEMBL1904704 1.00 5/20
SCHEMBL1904707 SCHEMBL1904707 1.00 5/20
SCHEMBL1904709 SCHEMBL1904709 1.00 5/20
SCHEMBL4410661 SCHEMBL4410661 1.00 5/20
SCHEMBL4410666 SCHEMBL4410666 1.00 5/20
SCHEMBL4412367 SCHEMBL4412367 1.00 5/20
SCHEMBL4412376 SCHEMBL4412376 1.00 5/20

Clinical trials — most relevant to DUSP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans PHASE4COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma PHASE1/PHASE2COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a DUSP1 binder may also engage these)

ProteinNameSimilarity
P28563 — 1.000 P28563 →
Q64623 — 1.000 Q64623 →
Q9PW71 — 0.992 Q9PW71 →
O54838 — 0.990 O54838 →
Q62767 — 0.989 Q62767 →
DUSP4 Dual specificity protein phosphatase 4 0.989 landscape →
Q16829 — 0.987 Q16829 →
Q91Z46 — 0.986 Q91Z46 →
Q63340 — 0.986 Q63340 →
Q90W58 — 0.986 Q90W58 →
Q91790 — 0.986 Q91790 →
DUSP5 Dual specificity protein phosphatase 5 0.985 landscape →
Q8BFV3 — 0.985 Q8BFV3 →
DUSP6 Dual specificity protein phosphatase 6 0.982 landscape →
Q9DBB1 — 0.982 Q9DBB1 →
Q2KJ36 — 0.981 Q2KJ36 →
Q64346 — 0.980 Q64346 →
Q05922 — 0.974 Q05922 →
Q9JIM4 — 0.972 Q9JIM4 →
Q99956 — 0.971 Q99956 →
Q0IID7 — 0.970 Q0IID7 →
Q9D0T2 — 0.970 Q9D0T2 →
Q9VVW5 — 0.970 Q9VVW5 →
Q9ESS0 — 0.968 Q9ESS0 →
DUSP10 Dual specificity protein phosphatase 10 0.967 landscape →
Q8BK84 — 0.966 Q8BK84 →
Q9H6T0 — 0.966 Q9H6T0 →
Q9JLY7 — 0.965 Q9JLY7 →
Q9UNI6 — 0.965 Q9UNI6 →
DUSP2 Dual specificity protein phosphatase 2 0.965 landscape →